SPEN Inactivation Drives Resistance to Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer

In real-world cohorts, loss of SPEN function across genomic, transcriptomic, and protein levels is associated with reduced benefit from androgen receptor pathway inhibitors therapy in metastatic prostate cancer.